Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclamen europaeum extract is a botanical drug product derived from the tubers of the *Cyclamen europaeum* plant, containing triterpenoid saponins (primarily cyclamin). It is formulated as a nasal spray for the treatment of acute and chronic rhinosinusitis. The mechanism of action involves the local irritation of the nasal mucosa, which stimulates the trigeminal nerve endings. This stimulation triggers a reflex seromucous discharge, facilitating the drainage of accumulated mucus from the paranasal sinuses and reducing mucosal edema. It is marketed in various regions under the brand name Nasodren.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclamen europaeum extract.